10x Genomics, Inc. ($TXG) Stock Forecast: Down 6.8% Today

What is 10x Genomics, Inc.?

TXG is a biotechnology company specializing in genomics, known for its innovative solutions in the field. The overall market sentiment has been positive towards the company.

Why is 10x Genomics, Inc. going down?

TXG stock is down 6.8% on Aug 8, 2025 13:51

• Despite surpassing Q2 earnings and revenue estimates significantly, TXG experienced a bearish movement.
• Investors might have had high expectations already priced into the stock, leading to a sell-off post-earnings.
• The market might be reacting to forward-looking guidance or other factors not captured in the earnings report, causing the bearish movement.
• This could be a classic case of "buy the rumor, sell the news" scenario, where investors take profits after a positive earnings surprise.

TXG Price Chart

TXG Technical Analysis

TXG News

10x Genomics ( TXG ) Surpasses Q2 Earnings and Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of +180.00% and +24.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2680550/10x-genomics-txg-surpasses-q2-earnings-and-revenue-estimates

Trending Today

Avalanche ($AVAX) Crypto Forecast: Down 5.0% Today

Immutable ($IMX) Crypto Forecast: Down 6.2% Today

Polkadot ($DOT) Crypto Forecast: Down 5.4% Today

Chainlink ($LINK) Crypto Forecast: Down 5.0% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.4% Today

SoFi Technologies Inc. ($SOFI) Stock Forecast: Up 5.2% Today

Microsoft Corporation ($MSFT) Stock Forecast: Up 2.0% Today

Fiverr International Ltd. ($FVRR) Stock Forecast: Up 7.4% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.5% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Down 5.1% Today

10x Genomics, Inc. Price History

08.07.2025 - TXG Stock was down 6.8%

• Despite surpassing Q2 earnings and revenue estimates significantly, TXG experienced a bearish movement.
• Investors might have had high expectations already priced into the stock, leading to a sell-off post-earnings.
• The market might be reacting to forward-looking guidance or other factors not captured in the earnings report, causing the bearish movement.
• This could be a classic case of "buy the rumor, sell the news" scenario, where investors take profits after a positive earnings surprise.

11.09.2024 - TXG Stock was up 12.0%

• Despite Q3 sales underperforming, the CEO's positive outlook on future opportunities potentially boosted investor confidence in 10x Genomics' long-term growth.
• Speculations suggest that Ark Invest's shift away from Moderna Inc. may have prompted some investors to consider alternative biotech companies like 10x Genomics, influencing the stock's rise.
• The general bullish market sentiment included optimism towards firms with growth potential in genomic technology, increasing the demand for 10x Genomics shares.

30.09.2024 - TXG Stock was up 5.8%

• Despite a decrease in instrument sales affecting Q3 earnings, TXG experienced a significant bullish surge today.
• Investor sentiment may be buoyed by the potential for growth in consumable sales, which helped mitigate the drop in instrument sales.
• The market appears to appreciate the company's emphasis on consumables as a more reliable source of revenue compared to instrument sales.
• This uptick in activity could suggest that investors have confidence in 10x Genomics' capability to overcome obstacles and expand into new revenue streams.

11.09.2024 - TXG Stock was up 5.4%

• TXG stock faced a decline after the Q3 sales results were below expectations, disappointing investors.
• The lackluster performance in Q3 may have raised concerns about the company's future growth and its ability to meet market forecasts.
• The decision by Ark Invest to sell off Moderna stock, despite positive post-COVID plans, likely added to a sense of caution in the biotech sector, impacting companies like 10x Genomics.
• In sum, the blend of TXG's financial results and the broader market dynamics probably contributed to the stock's downward movement today.

31.09.2024 - TXG Stock was down 3.8%

• Despite a loss in the third quarter, 10x Genomics (TXG) exceeded market expectations for earnings per share, potentially triggering a positive market sentiment initially.
• Nevertheless, a drop in instrument sales for the gene sequencing technology in the third quarter resulted in a negative trend for TXG stock, raising concerns among investors regarding revenue growth prospects.
• The conflicting outcomes of surpassing earnings expectations while encountering a decrease in sales underscored the market's emphasis on revenue generation and future growth potential for 10x Genomics, leading to the downward movement in the stock price.

09.04.2025 - TXG Stock was down 1.7%

• The reported Q1 loss by TXG may have raised concerns among investors about the company's financial health, leading to a bearish movement in the stock.
• Despite topping revenue estimates, the larger-than-expected loss could have overshadowed the positive revenue performance, contributing to the downward trend in TXG's stock price.
• Investors might be cautious about the future prospects of TXG, waiting for more clarity on the factors behind the reported loss and its potential impact on the company's growth trajectory.

05.01.2025 - TXG Stock was up 5.7%

• Despite worries about negative earnings expectations, 10x Genomics (TXG) surprised the market with a strong bullish performance, indicating positive investor sentiment.
• Trades by Ark Invest, led by Cathie Wood, did not directly impact 10x Genomics (TXG) stock, allowing it to stand out positively in today's market.
• The bullish movement in 10x Genomics (TXG) stock may be linked to favorable internal developments, suggesting potential positive upcoming earnings despite initial apprehensions.

29.04.2025 - TXG Stock was up 5.4%

• Analysts have established an average price target for TXG, signaling a potential upside of 43.1% and demonstrating favorable sentiment toward the stock.
• Upward revisions in earnings estimates for TXG may have played a role in the market's bullish movement.
• Investor confidence in TXG's growth prospects and advancements in gene sequencing technology likely contributed to the optimistic market sentiment.

14.04.2025 - TXG Stock was down 5.0%

• Despite analysts forecasting a potential upside of 55.9% for TXG, the stock exhibited a bearish movement today.
• The Q1 earnings report revealed a 20% earnings surprise and 16.24% revenue beat, which could have initially fueled positive investor sentiment.
• However, undisclosed factors within the report likely triggered a negative market response, resulting in today's bearish movement in TXG.
• Concerns about the company's future prospects or broader market conditions may be contributing to the decline in TXG's stock price.

14.01.2025 - TXG Stock was up 7.6%

• Despite posting a Q4 loss and missing EPS estimates, 10x Genomics (TXG) had a strong bullish movement, indicating that investors are focusing on other positive aspects of the company.
• The company's revenue exceeding estimates could have contributed to the bullish movement, showing potential growth opportunities and market confidence in its products and services.
• The market might be optimistic about 10x Genomics' future prospects, especially with its 2025 sales guidance, even though it falls slightly below consensus, suggesting long-term growth potential.
• Investors may be overlooking short-term profitability concerns and focusing more on the company's revenue performance and strategic direction, driving the bullish movement in the stock.

13.01.2025 - TXG Stock was down 5.7%

• TXG reported a Q4 loss, which was lower than expected by 25%.
• Despite topping revenue estimates slightly, the market reacted negatively to the earnings miss.
• Investors might be concerned about the company's future performance and profitability, leading to the bearish movement in the stock price.
• The market sentiment towards TXG seems to be influenced by the disappointing earnings report, causing a sell-off in the stock.

02.04.2025 - TXG Stock was up 5.1%

• Despite concerns about negative earnings, investors may be optimistic about potential future growth prospects or other positive developments within the company.
• The bullish movement could indicate that investors are looking beyond short-term earnings and focusing on the long-term potential of 10x Genomics.
• Market sentiment may have been swayed by positive industry trends or broader market conditions, leading to the bullish movement in TXG's stock price.